Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorBARLESI, F.
dc.contributor.authorGARON, E.
dc.contributor.authorKIM, D-W.
dc.contributor.authorFELIP, E.
dc.contributor.authorHAN, J-Y.
dc.contributor.authorKIM, J-H.
dc.contributor.authorAHN, M-J. A.
dc.contributor.authorFIDLER, M. J.
dc.contributor.authorGUBENS, M. A.
dc.contributor.authorCASTRO, G.
dc.contributor.authorSURMONT, V.
dc.contributor.authorLI, Q.
dc.contributor.authorDEITZ, A. C.
dc.contributor.authorLUBINIECKI, G.
dc.contributor.authorHERBST, R. S.
dc.date.accessioned2017-05-19T14:08:51Z
dc.date.available2017-05-19T14:08:51Z
dc.date.issued2016
dc.description.indexMEDLINE
dc.description.sponsorshipMerck Co., Inc.
dc.identifier.citationANNALS OF ONCOLOGY, v.27, suppl.6, 2016
dc.identifier.eissn1569-8041
dc.identifier.issn0923-7534
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/19828
dc.language.isoeng
dc.publisherOXFORD UNIV PRESS
dc.relation.ispartofAnnals of Oncology
dc.rightsrestrictedAccess
dc.rights.holderCopyright OXFORD UNIV PRESS
dc.subject.wosOncology
dc.titleAssessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC
dc.typeconferenceObject
dc.type.categorymeeting abstract
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryFrança
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryBélgica
hcfmusp.affiliation.countryCoréia do Sul
hcfmusp.affiliation.countryEspanha
hcfmusp.affiliation.countryisofr
hcfmusp.affiliation.countryisous
hcfmusp.affiliation.countryisokr
hcfmusp.affiliation.countryisoes
hcfmusp.affiliation.countryisobe
hcfmusp.author.externalBARLESI, F.:Aix Marseille Univ, Oncol, Assistance Publ Hop Marseille, Marseille, France
hcfmusp.author.externalGARON, E.:Univ Calif Los Angeles, David Geffen Sch Med, Med Hematol & Oncol, Santa Monica, CA USA
hcfmusp.author.externalKIM, D-W.:Seoul Natl Univ Hosp, Internal Med, Seoul, South Korea
hcfmusp.author.externalFELIP, E.:Vall dHebron Univ Hosp, Med Oncol, Inst Oncol, Barcelona, Spain
hcfmusp.author.externalHAN, J-Y.:Natl Canc Ctr, Translat & Clin Res, Goyang, South Korea
hcfmusp.author.externalKIM, J-H.:CHA Univ, CHA Bundang Med Ctr, Dept Oncol, Gyeonggi Do, South Korea
hcfmusp.author.externalAHN, M-J. A.:Samsung Med Ctr, Med Oncol, Seoul, South Korea
hcfmusp.author.externalFIDLER, M. J.:Rush Univ, Med Ctr, Internal Med, Chicago, IL 60612 USA
hcfmusp.author.externalGUBENS, M. A.:Univ Calif San Francisco, Dept Med, San Francisco, CA USA
hcfmusp.author.externalSURMONT, V.:Univ Ziekenhuis Ghent, Med Oncol, Ghent, Belgium
hcfmusp.author.externalLI, Q.:Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
hcfmusp.author.externalDEITZ, A. C.:Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
hcfmusp.author.externalLUBINIECKI, G.:Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
hcfmusp.author.externalHERBST, R. S.:Yale Sch Med, Med Oncol, New Haven, CT USA
hcfmusp.contributor.author-fmusphcGILBERTO DE CASTRO JUNIOR
hcfmusp.description.issuesuppl 6
hcfmusp.description.volume27
hcfmusp.origemWOS
hcfmusp.origem.wosWOS:000393913000311
hcfmusp.publisher.cityOXFORD
hcfmusp.publisher.countryENGLAND
relation.isAuthorOfPublication0df25c0f-1337-424e-b0f7-41d0fccb51fc
relation.isAuthorOfPublication.latestForDiscovery0df25c0f-1337-424e-b0f7-41d0fccb51fc
Arquivos
Coleções
Comunicações em Eventos - HC/ICESP
Comunicações em Eventos - LIM/24